CO6311000A2 - MODIFIED POLYPEPTIDES OF FACTOR IX WITH ONE OR MORE GLYCOSILATION SITES INTRODUCED - Google Patents

MODIFIED POLYPEPTIDES OF FACTOR IX WITH ONE OR MORE GLYCOSILATION SITES INTRODUCED

Info

Publication number
CO6311000A2
CO6311000A2 CO10128682A CO10128682A CO6311000A2 CO 6311000 A2 CO6311000 A2 CO 6311000A2 CO 10128682 A CO10128682 A CO 10128682A CO 10128682 A CO10128682 A CO 10128682A CO 6311000 A2 CO6311000 A2 CO 6311000A2
Authority
CO
Colombia
Prior art keywords
factor
polypeptides
sites introduced
modified polypeptides
modified factor
Prior art date
Application number
CO10128682A
Other languages
Spanish (es)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Health Care Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Health Care Llc filed Critical Bayer Health Care Llc
Publication of CO6311000A2 publication Critical patent/CO6311000A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se divulgan polipéptidos modificados del factor IX, tales como los polipéptidos del factor IX con uno o más sitios de glicosilación introducidos. Los polipéptidos modificados del factor IX pueden exhibir un incremento de la estabilidad in vitro o in vivo, tal como una semivida plasmática más prolongada. Asimismo se divulgan procedimientos de fabricar polipéptidos modificados del factor IX y a procedimientos de usar modificados del factor IX para, por ejemplo, tratar a pacientes afectados por hemofilia B.Modified factor IX polypeptides, such as factor IX polypeptides with one or more glycosylation sites introduced are disclosed. Modified factor IX polypeptides may exhibit increased stability in vitro or in vivo, such as a longer plasma half-life. Methods of manufacturing modified factor IX polypeptides and methods of using modified factor IX are also disclosed to, for example, treat patients affected by hemophilia B.

CO10128682A 2008-04-16 2010-10-15 MODIFIED POLYPEPTIDES OF FACTOR IX WITH ONE OR MORE GLYCOSILATION SITES INTRODUCED CO6311000A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
CO6311000A2 true CO6311000A2 (en) 2011-08-22

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10128682A CO6311000A2 (en) 2008-04-16 2010-10-15 MODIFIED POLYPEPTIDES OF FACTOR IX WITH ONE OR MORE GLYCOSILATION SITES INTRODUCED

Country Status (17)

Country Link
EP (1) EP2288622A4 (en)
JP (1) JP2011517951A (en)
KR (1) KR20110005862A (en)
CN (1) CN102083856A (en)
AU (1) AU2009244633A1 (en)
BR (1) BRPI0910702A2 (en)
CA (1) CA2721683A1 (en)
CO (1) CO6311000A2 (en)
CR (1) CR11737A (en)
DO (1) DOP2010000311A (en)
EC (1) ECSP10010551A (en)
IL (1) IL208718A0 (en)
MX (1) MX2010011345A (en)
RU (1) RU2010146387A (en)
SG (1) SG189790A1 (en)
SV (1) SV2010003704A (en)
WO (1) WO2009137254A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
CN102026653B (en) * 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 Human factor IX variants with an extended half life
ES2940323T3 (en) 2008-09-15 2023-05-05 Uniqure Biopharma B V Factor IX polypeptide mutant, its uses and a method for its production
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI557135B (en) 2010-11-03 2016-11-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
SI2717898T1 (en) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
EP2842966B1 (en) 2012-04-27 2018-08-15 Nihon University Therapeutic agent for epithelial and endothelial injury
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2900328A4 (en) 2012-09-25 2016-05-11 Biogen Ma Inc Methods of using fix polypeptides
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
PL2956477T3 (en) 2013-02-15 2021-06-14 Bioverativ Therapeutics Inc. Optimized factor viii gene
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
ES2900425T3 (en) 2013-09-25 2022-03-16 Bioverativ Therapeutics Inc Column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EA038573B1 (en) 2014-03-24 2021-09-16 Биовератив Терапьютикс Инк. Lyophilized factor ix formulation for preventing bleeding episodes
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR112018002150A2 (en) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc factor ix fusion proteins and methods of manufacturing and using them
US11753461B2 (en) 2016-02-01 2023-09-12 Bioverativ Therapeutics Inc. Optimized factor VIII genes
CN105695616A (en) * 2016-04-22 2016-06-22 王冬国 Analysis marker for diagnosing thyroid cancer and application thereof
CN110520150A (en) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 Use the method for chimeric coagulation factor therapies hemophilic arthosis
EA201991768A1 (en) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
FR3069540B1 (en) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
CA3072334A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
RU2020114616A (en) 2017-09-27 2021-10-28 Сайджилон Терапьютикс, Инк. METHODS, COMPOSITIONS AND IMPLANTED ELEMENTS CONTAINING ACTIVE CELLS
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
KR20210005608A (en) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. Implantable Particles and Related Methods
CN113227385A (en) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
KR20220009389A (en) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. Composition of exosomes and AAV
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US11670855B2 (en) 2021-02-24 2023-06-06 Bluehalo, Llc System and method for a digitally beamformed phased array feed

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
RU2004110239A (en) * 2001-09-04 2005-10-20 Мерк Патент ГмбХ (DE) MODIFIED FACTOR IX
US20050008580A1 (en) * 2003-04-09 2005-01-13 Wyeth Hemophilia treatment by inhalation of coagulation factors
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0417341A (en) * 2003-12-03 2007-04-17 Neose Technologies Inc glyceguiled factor ix
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
AU2009244633A1 (en) 2009-11-12
RU2010146387A (en) 2012-05-27
CN102083856A (en) 2011-06-01
EP2288622A2 (en) 2011-03-02
WO2009137254A2 (en) 2009-11-12
ECSP10010551A (en) 2010-11-30
KR20110005862A (en) 2011-01-19
IL208718A0 (en) 2010-12-30
SV2010003704A (en) 2011-02-21
MX2010011345A (en) 2011-02-23
CA2721683A1 (en) 2009-11-12
SG189790A1 (en) 2013-05-31
DOP2010000311A (en) 2011-02-28
BRPI0910702A2 (en) 2016-07-05
WO2009137254A3 (en) 2010-01-14
JP2011517951A (en) 2011-06-23
EP2288622A4 (en) 2012-04-18
CR11737A (en) 2011-02-07

Similar Documents

Publication Publication Date Title
CO6311000A2 (en) MODIFIED POLYPEPTIDES OF FACTOR IX WITH ONE OR MORE GLYCOSILATION SITES INTRODUCED
CR20120052A (en) MODIFIED FACTOR IX POLIPEPTIDES AND USES OF THE SAME
ECSP12011908A (en) OCTAHIDROPIRROLO [3,4-c] PIRROLOS DISUSTITUIDOS AS
IN2014DN09782A (en)
DOP2016000042A (en) ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME
BRPI0920914A8 (en) ALPHA-KETO PERACIDS AND METHODS FOR PRODUCING AND USING THEM.
CO6331368A2 (en) MODIFIED POLIPEPTIDE FACTORS VII (FVII)
DOP2011000188A (en) SIRTUINE MODULATING THIAZOLOPIRIDIN COMPOUNDS
MY162576A (en) Modified factor ix polypeptides and uses thereof
ECSP088633A (en) MODIFIED LISINE MIMETIC COMPOUNDS
SV2011003855A (en) HETEROARILOS SUBSTITUTED
CR11866A (en) DERIVATIVES OF PIRIDINO-PIRIDINONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
CR20110630A (en) CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS
UY30479A1 (en) BENZOFUR- AND BENZOTIENOPIRIMIDINE MODULATORS OF THE H4 HISTAMINE RECEIVER
GT200900309A (en) DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
BR112012013487A2 (en) AMANTADINE COMPOSITIONS AND METHODS OF USE
UY34584A (en) PROCESS FOR RECOVERING MOLIBDATE IN A DESLIGNIFICATION OF PULP CATALYZED BY MOLIBDATE WITH HYDROGEN PEROXIDE
NZ721918A (en) Modified serpins for the treatment of bleeding disorders
DOP2010000251A (en) EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL
MX2012001409A (en) Modified agrin-fragment capable of restoring muscle strength for use as a medicament.
ECSP13012613A (en) METHOD FOR PRODUCING AND USING A SOUND CARBOXIMETILCELLULOSE AND GOSIPOL COPOLYMER
DOP2010000346A (en) 4- (3-CHLORO-2-FLUOROANILINO) DIFUMARATE SALT -7-METOXI-6 - {[1- (N-METILCARBAMOILMETIL) PIPERIDIN-4-IL] OXI} QUINAZOLINE
CL2011002619A1 (en) Compounds derived from arylsulfonamides, modulators of ccr3 receptor activity; pharmaceutical composition comprising them; Useful in the treatment of an inflammatory disease such as asthma, allergic rhinitis, atopic dermatitis, epoc among others.
UY32975A (en) AMINOPIRIDINE DERIVATIVES
EA201390350A1 (en) REMEDIAL MEANS CONTAINING POLYETHYLENE GLYCOL AND ELECTROLYTES

Legal Events

Date Code Title Description
FG Application granted